Literature DB >> 23249763

Immunising with the transmembrane envelope proteins of different retroviruses including HIV-1: a comparative study.

Joachim Denner1.   

Abstract

The induction of neutralizing antibodies is a promising way to prevent retrovirus infections. Neutralizing antibodies are mainly directed against the envelope proteins, which consist of two molecules, the surface envelope (SU) protein and the transmembrane envelope (TM) protein. Antibodies broadly neutralizing the human immunodeficiencvy virus-1 (HIV-1) and binding to the TM protein gp41 of the virus have been isolated from infected individuals. Their epitopes are located in the membrane proximal external region (MPER). Since there are difficulties to induce such neutralizing antibodies as basis for an effective AIDS vaccine, we performed a comparative analysis immunising with the TM proteins of different viruses from the family Retroviridae. Both subfamilies, the Orthoretrovirinae and the Spumaretrovirinae were included. In this study, the TM proteins of three gammaretroviruses including (1) the porcine endogenous retrovirus (PERV), (2) the Koala retrovirus (KoRV), (3) the feline leukemia virus (FeLV), of two lentiviruses, HIV-1, HIV-2, and of two spumaviruses, the feline foamy virus (FFV) and the primate foamy virus (PFV) were used for immunisation. Whereas in all immunisation studies binding antibodies were induced, neutralizing antibodies were only found in the case of the gammaretroviruses. The induced antibodies were directed against the MPER and the fusion peptide proximal region (FPPR) of their TM proteins; however only the antibodies against the MPER were neutralizing. Most importantly, the epitopes in the MPER were localized in the same position as the epitopes of the antibodies broadly neutralizing HIV-1 in the TM protein gp41 of HIV-1, indicating that the MPER is an effective target for the neutralization of retroviruses.

Entities:  

Keywords:  AIDS; neutralizing antibodies; retroviruses; spumaviruses; transmembrane envelope proteins

Mesh:

Substances:

Year:  2012        PMID: 23249763      PMCID: PMC3891701          DOI: 10.4161/hv.23221

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  74 in total

1.  The membrane-proximal external region of HIV-1 gp41: a vaccine target worth exploring.

Authors:  Michael B Zwick
Journal:  AIDS       Date:  2005-11-04       Impact factor: 4.177

2.  Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays.

Authors:  Regina Hofmann-Lehmann; Ravi Tandon; Felicitas S Boretti; Marina L Meli; Barbara Willi; Valentino Cattori; Maria A Gomes-Keller; Pete Ossent; Matthew C Golder; J Norman Flynn; Hans Lutz
Journal:  Vaccine       Date:  2005-09-19       Impact factor: 3.641

3.  The HIV-neutralizing monoclonal antibody 4E10 recognizes N-terminal sequences on the native antigen.

Authors:  Christine Hager-Braun; Hermann Katinger; Kenneth B Tomer
Journal:  J Immunol       Date:  2006-06-15       Impact factor: 5.422

4.  Foamy virus Bet proteins function as novel inhibitors of the APOBEC3 family of innate antiretroviral defense factors.

Authors:  Rebecca A Russell; Heather L Wiegand; Michael D Moore; Alexandra Schäfer; Myra O McClure; Bryan R Cullen
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Mucosal and systemic antibody responses in humans infected with simian foamy virus.

Authors:  James E Cummins; Roumiana S Boneva; William M Switzer; Logan L Christensen; Paul Sandstrom; Walid Heneine; Louisa E Chapman; Charlene S Dezzutti
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

6.  The requirements and mechanism for capsid assembly and budding of bovine foamy virus.

Authors:  X H Kong; H Yu; C H Xuan; J Z Wang; Q M Chen; Y Q Geng
Journal:  Arch Virol       Date:  2005-04-18       Impact factor: 2.574

7.  Neutralising antibodies against the transmembrane protein of feline leukaemia virus (FeLV).

Authors:  S Langhammer; U Fiebig; R Kurth; J Denner
Journal:  Vaccine       Date:  2005-05-09       Impact factor: 3.641

8.  Antibodies neutralizing feline leukaemia virus (FeLV) in cats immunized with the transmembrane envelope protein p15E.

Authors:  Stefan Langhammer; Janine Hübner; Reinhard Kurth; Joachim Denner
Journal:  Immunology       Date:  2006-02       Impact factor: 7.397

9.  Transspecies transmission of the endogenous koala retrovirus.

Authors:  Uwe Fiebig; Manuel Garcia Hartmann; Norbert Bannert; Reinhard Kurth; Joachim Denner
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

10.  Use of endogenous retroviral sequences (ERVs) and structural markers for retroviral phylogenetic inference and taxonomy.

Authors:  Patric Jern; Göran O Sperber; Jonas Blomberg
Journal:  Retrovirology       Date:  2005-08-10       Impact factor: 4.602

View more
  12 in total

1.  Sequence variation of koala retrovirus transmembrane protein p15E among koalas from different geographic regions.

Authors:  Yasuko Ishida; Chelsea McCallister; Nikolas Nikolaidis; Kyriakos Tsangaras; Kristofer M Helgen; Alex D Greenwood; Alfred L Roca
Journal:  Virology       Date:  2014-11-22       Impact factor: 3.616

2.  Novel neutralising antibodies targeting the N-terminal helical region of the transmembrane envelope protein p15E of the porcine endogenous retrovirus (PERV).

Authors:  Alexander Waechter; Joachim Denner
Journal:  Immunol Res       Date:  2014-01       Impact factor: 2.829

3.  Complete Genome Characterization of Reticuloendotheliosis Virus Detected in Chickens with Multiple Viral Coinfections.

Authors:  Ruy D Chacón; Benjy Sedano-Herrera; Elizabeth Regina Alfaro-Espinoza; Wilma Ursula Quispe; Arturo Liñan-Torres; David De la Torre; Anderson de Oliveira; Claudete S Astolfi-Ferreira; Antonio J Piantino Ferreira
Journal:  Viruses       Date:  2022-04-13       Impact factor: 5.818

4.  Induction of neutralizing antibodies specific for the envelope proteins of the koala retrovirus by immunization with recombinant proteins or with DNA.

Authors:  Uwe Fiebig; Britta Dieckhoff; Christian Wurzbacher; Annekathrin Möller; Reinhard Kurth; Joachim Denner
Journal:  Virol J       Date:  2015-04-30       Impact factor: 4.099

5.  Antibody response against koala retrovirus (KoRV) in koalas harboring KoRV-A in the presence or absence of KoRV-B.

Authors:  O Olagoke; B L Quigley; M V Eiden; P Timms
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

Review 6.  Koala retroviruses: characterization and impact on the life of koalas.

Authors:  Joachim Denner; Paul R Young
Journal:  Retrovirology       Date:  2013-10-23       Impact factor: 4.602

7.  Single Amino Acid Substitution N659D in HIV-2 Envelope Glycoprotein (Env) Impairs Viral Release and Hampers BST-2 Antagonism.

Authors:  François E Dufrasne; Catherine Lombard; Patrick Goubau; Jean Ruelle
Journal:  Viruses       Date:  2016-10-14       Impact factor: 5.048

Review 8.  Koala retrovirus epidemiology, transmission mode, pathogenesis, and host immune response in koalas (Phascolarctos cinereus): a review.

Authors:  Mohammad Enamul Hoque Kayesh; Md Abul Hashem; Kyoko Tsukiyama-Kohara
Journal:  Arch Virol       Date:  2020-08-08       Impact factor: 2.574

9.  Induction of neutralizing antibody response against koala retrovirus (KoRV) and reduction in viral load in koalas following vaccination with recombinant KoRV envelope protein.

Authors:  O Olagoke; D Miller; F Hemmatzadeh; T Stephenson; J Fabijan; P Hutt; S Finch; N Speight; P Timms
Journal:  NPJ Vaccines       Date:  2018-08-02       Impact factor: 7.344

Review 10.  Vaccination against the Koala Retrovirus (KoRV): Problems and Strategies.

Authors:  Joachim Denner
Journal:  Animals (Basel)       Date:  2021-12-14       Impact factor: 2.752

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.